Galvus Approval Delayed While FDA Reviews Safety Data


By: dhtest

Novartis reports that there will be a three-month delay in approval for its experimental diabetes drug, Galvus, due to the FDA’s request for additional safety data.

On November 13, 2006, Novartis announced that it is submitting further data to the FDA, “meaning that the U.S. regulator’s decision on approving the product will probably come at the end of February, 2007, three months later than expected.”

Galvus is a DPP-IV inhibitor that works by enhancing the body’s own ability to lower blood sugar levels. Merck Co.’s Januvia is also a DPP-IV inhibitor, which was granted FDA approval in October 2006.



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.